Mar 4, 2026 04:01PM
Feb 26, 2026 04:01PM
Feb 23, 2026 07:00AM
Feb 19, 2026 07:00AM
Feb 5, 2026 07:00AM
Feb 4, 2026 04:01PM
Jan 12, 2026 07:08AM Syndax reports $277 million combined revenue for cancer drugs in 2025
Jan 12, 2026 07:00AM
Jan 7, 2026 07:00AM
Jan 5, 2026 07:00AM
Dec 12, 2025 07:00AM
Dec 9, 2025 04:34AM
Dec 8, 2025 06:50AM
Dec 8, 2025 06:50AM Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
Dec 3, 2025 04:01PM
Dec 1, 2025 07:00AM
Nov 5, 2025 04:01PM
Nov 3, 2025 04:01PM
Nov 3, 2025 09:09AM
Nov 3, 2025 09:08AM
Nov 3, 2025 09:08AM Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
Oct 30, 2025 07:00AM
Oct 27, 2025 07:48AM
Oct 27, 2025 07:00AM
Oct 24, 2025 01:59PM
Oct 24, 2025 01:58PM
Oct 24, 2025 01:08PM
Oct 3, 2025 04:01PM Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 19, 2025 07:00AM
Sep 19, 2025 07:00AM
Aug 26, 2025 07:00AM
Aug 4, 2025 04:01PM
Jul 28, 2025 07:00AM
Jun 24, 2025 04:02PM
Jun 24, 2025 04:01PM Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
Jun 12, 2025 12:03PM
Jun 12, 2025 12:02PM
Jun 12, 2025 07:00AM
Jun 12, 2025 07:00AM
May 29, 2025 07:00AM
May 14, 2025 09:30AM
May 14, 2025 09:30AM Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
May 12, 2025 04:01PM
May 8, 2025 07:00AM
May 7, 2025 04:01PM
May 6, 2025 07:09AM
May 5, 2025 04:01PM
Apr 28, 2025 07:00AM
Apr 2, 2025 07:00AM Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
Mar 3, 2025 01:06PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All